Gilead Sciences (XSWX:GILD) Other Stockholders Equity: CHF0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GILD Gilead Sciences Inc XSWX:GILD
69 GF Score
Price CHF106.02
GF Value CHF78.37
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Other Stockholders Equity?

Gilead Sciences XSWX:GILD -0.39% 69 Other Stockholders Equity is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:GILD with a GF Score™ of 69/100 and a GF Value™ of CHF78.37. The stock has 3 warning signs investors should review.

Gilead Sciences's Other Stockholders Equity for the quarter that ended in Mar. 2026 was CHF0 Mil.

Gilead Sciences's quarterly Other Stockholders Equity declined from Sep. 2025 (CHF0 Mil) to Dec. 2025 (CHF-0 Mil) but then increased from Dec. 2025 (CHF-0 Mil) to Mar. 2026 (CHF0 Mil).

Gilead Sciences's annual Other Stockholders Equity increased from Dec. 2023 (CHF0 Mil) to Dec. 2024 (CHF0 Mil) but then declined from Dec. 2024 (CHF0 Mil) to Dec. 2025 (CHF-0 Mil).

Gilead Sciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Other Stockholders Equity Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 0.00
XSWX:GILD
69GF Score
Gilead Sciences Inc XSWX:GILD
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of CHF0 Mil mean?
Gilead Sciences (XSWX:GILD) has a Other Stockholders Equity of CHF0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Other Stockholders Equity too high?
Gilead Sciences' current Other Stockholders Equity is CHF0 Mil. Overall, Gilead Sciences has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Other Stockholders Equity compare to PFE and AMGN?
Gilead Sciences' Other Stockholders Equity of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Other Stockholders Equity is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Gilead Sciences (XSWX:GILD) has a current Other Stockholders Equity of CHF0 Mil. The stock's GF Value™ is CHF78.37, compared to a current price of CHF106.02 — trading 35.3% above its estimated fair value. The current Other Stockholders Equity is CHF0 Mil. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Gilead Sciences (XSWX:GILD), the current Other Stockholders Equity is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (XSWX:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of CHF106.02 is trading 35.3% above its estimated GF Value™ of CHF78.37.

Key valuation signals for XSWX:GILD:

  • Other Stockholders Equity: CHF0 Mil
  • GF Value™: CHF78.37 vs. price of CHF106.02 (35.3% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the XSWX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for XSWX:GILD

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF106.02
Price
CHF78.37
GF Value